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Abstract 
Leukocytoclastic vasculitis is a multicausal systemic inflammatory disease of the small vessels, 
histologically characterized by inflammation and deposition of both nuclear debris and fibrin 
in dermal postcapillary venules. The clinical picture typically involves palpable purpura of the 
lower legs and may be associated with general symptoms such as fatigue, arthralgia and 
fever.  Involvement  of  the  internal  organs,  most  notably  the  kidneys,  the  central  nervous 
system or the eyes, is possible and determines the prognosis. Oxaliplatin-induced leukocyto-
clastic vasculitis is a very rare event that limits treatment options in affected patients. We 
report 2 patients who developed the condition under chemotherapy for advanced rectal and 
metastatic  colon  carcinoma,  respectively;  a  termination  of  the  therapy  was  therefore 
necessary.  While  current  therapies  for  colorectal  cancer  include  the  combination  of 
multimodal treatment with new and targeted agents, rare and unusual side effects elicited by 
established agents also need to be taken into account for the clinical management.  
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Background 
The current standard of treatment for locally advanced rectal cancer (UICC stages II and 
III)  includes  a  5-fluorouracil  (5-FU)-based  preoperative  radiochemotherapy  (RCT),  total 
mesorectal  excision, and postoperative chemotherapy  [1, 2]. Several  randomized clinical 
trials  during  the  last  decades  have  demonstrated  that  neoadjuvant  5-FU-based  RCT 
significantly improves locoregional control of rectal cancer [3, 4]. Today, the limitation of the 
prognosis of individual patients is mainly determined by the occurrence of distant metasta-
ses  in  3040%  of  patients.  This  led  to  the  intensification  of  systemic  therapy  through 
integration of platinum derivatives [5], an approach that not only promises a therapeutic 
benefit but simultaneously bears the risk of increased toxicity [6]. Subsequently, to avoid 
unnecessary  toxicity,  more  individualized  and  risk-adapted  treatment  approaches  are 
needed and are currently being validated in several ongoing clinical trials. However, in rectal 
cancer, reliable biomarkers to predict the response to neoadjuvant RCT, individual prognosis 
and occurrence of treatment-associated toxicity have not yet been established as part of the 
clinical routine [7]. 
The adjuvant treatment strategy with 5-FU in combination with leucovorin and oxali-
platin is well established and has been used for nearly 10 years in the adjuvant treatment of 
UICC III colon cancer [8]. The neoadjuvant and adjuvant treatment with FOLFOX against 
locally advanced rectal cancer (UICC II and III) is integrated in several randomized phase III 
multicenter trials such as the CAO/ARO/AIO-04 trial of the German Rectal Cancer Study 
Group [7]. 
The CAO/ARO/AIO-04 regimen consists of intravenous oxaliplatin (80 mg/m2) com-
bined with leucovorin (400 mg/m2) and subsequent 5-FU infusion (2,400 mg/m2), repeated 
every  14  days  over  4  months  (8  cycles).  Oxaliplatin  is  a  platinum  derivative  whose 
therapeutic  effect  is  based  on  alkylating  effects.  The  platinum  compound  binds  to  DNA 
forming cross-links, which inhibit DNA replication and transcription, and so result in cell 
death [9, 10]. 
Oxaliplatin is mainly eliminated renally. For patients with chronic renal failure (creati-
nine clearance <30 ml/min), a dose reduction is necessary (starting dose of 65 mg/m2). 
Common adverse reactions of oxaliplatin (over 10%) include central neurological, gastroin-
testinal,  hematologic,  and  peripheral  neuropathic  reactions  [11].  Typical  side  effects  of 
oxaliplatin are a grade 3–4 neutropenia and in rare cases neutropenic fever. The myelosup-
pressing side effect can induce mild anemia and thrombocytopenia. 
The main gastrointestinal adverse effects are nausea, vomiting, and diarrhea [12]. The 
peripheral neuropathy is very common; it might affect the patient’s quality of life and might 
therefore lead to dose reductions [13]. The acute form is characterized by peripheral, acral 
and facial paresthesia and pain, commonly being exacerbated by exposure to the cold. The 
symptoms usually subside spontaneously after hours or days. The chronic side effects of 
neuropathy  grade  34  with  decreased  distal  sensation  and  proprioception  affect  the 
extremities and are reversible in most patients [14]. Of note, cutaneous symptoms after 
application of oxaliplatin are very rare [13]. 
Here we report on 2 cases of oxaliplatin-induced leukocytoclastic vasculitis with kidney 
involvement, a side effect which – to the best of our knowledge – was only reported in a 
single case before [15]. Written informed consent was obtained from the patients for the 
publication of this paper and any accompanying images.  
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A 75-year-old man presented with a locally advanced adenocarcinoma of the rectum (37 
cm above the anal verge, endoscopically staged as uT3 uN). As he had received interstitial 
brachytherapy (>145 Gy) 2 years before as a treatment for prostate cancer (cT2b, cNx, cM0, 
Gleason score 6), the standard treatment of neoadjuvant RCT with 50.4 Gy and concomitant 
5-FU  (+/-  oxaliplatin) was  not  possible. An  abdomino-perineal  rectum  exstirpation with 
implantation of a descendostoma was performed to remove the rectal cancer. The histo-
pathological  work-up  revealed  a  pT3a,  pN2b  (21/31),  cM0,  L1,  V0,  G3,  R0  (UICC  IIIB) 
adenocarcinoma and thus adjuvant chemotherapy was strongly suggested according to the 
vote of the institutional interdisciplinary tumor board. 
Eight weeks after surgery, the first cycle of adjuvant chemotherapy with 5-FU, leuco-
vorin and oxaliplatin (FOLFOX-6) was scheduled. The cycle consisted of a bimonthly regimen 
with intravenous oxaliplatin (80 mg/m2) and leucovorin (400 mg/m2) administered on day 
1.  5-FU  2,400  mg/m2  followed  on  day  1  as  a  continuous  infusion  for  46  h.  During  the 
following 3 days, the patient developed fever that resolved spontaneously. Fourteen days 
later, the patient showed disseminated petechiae with secondary hemorrhage, along with 
edema  on  both  legs  and  interdigital  ulceration.  He  reported  that  he  had  experienced 
arthralgia in his knees and elbows 4 days after the first dose of chemotherapy. His blood 
count  showed  microcytic,  hypochromic  anemia,  leukocytosis  of  13,900/µl,  elevated  C-
reactive protein of 90.1 mg/l, and an increase in the retention parameters (urea 25 mg/dl), 
indicating an affliction of the kidneys. The urine analysis was normal apart from an alkaline 
pH of 7.5. 
The chemotherapy was interrupted and the patient was admitted to the Department of 
Dermatology. On examination, there was palpable purpura with petechial hemorrhage on 
the lower limb in addition to massive edema on both lower legs (fig. 1). Some petechiae were 
also found on the lower arms and the abdomen. We suspected drug toxicity to be the cause 
of the skin lesions. A skin biopsy confirmed the diagnosis of leukocytoclastic vasculitis. The 
patient did not complain about abdominal pain and 3 tests for occult blood in the stool were 
negative. There was no evidence for a systemic vasculitis reaction. After 2 days, the renal 
parameters were rising (creatinine 1.33 mg/dl; normal range 0.5–1.0 mg/dl) and the patient 
developed  proteinuria  of  1,200  mg/day  in  the  24-hour  urine  collection.  Because  of  the 
putative  renal  involvement,  therapy  with  a  high-dose  corticosteroid  (prednisolone  80 
mg/day), a proton pump inhibitor (pantoprazole 40 mg/day) and osteoporosis prophylaxis 
(calcium carbonate and cholecalciferol 500 mg and 10 μg b.i.d., respectively) was initiated. In 
addition,  the  patient  was  prescribed  an  ACE-inhibitor  (ramipril  2.5  mg/day)  for  renal 
protection. 
An infectious origin of the leukocytoclastic vasculitis was considered implausible be-
cause there were no respective clinical symptoms and serological tests were negative for 
hepatitis A, B and C as well as for an infection with streptococci. The rheumatoid factors, C3c 
(1.37 g/l), C4 (0.25 g/l), p-ANCA-IF (<1:20), and ANA-IF (>1:80), were not elevated and no 
circulating immune complexes were detected. 
A punch biopsy from the active area of the frontal aspect of the right lower leg showed 
typical features of leukocytoclastic vasculitis (fig. 2). There were lymphocytic infiltrates with 
numerous neutrophils as well as ’nuclear dust’ in the higher corium, extravasated erythro-
cytes, focal small-vessel edema, endothelial cell swelling within the vessels and fibrinoid 
deposition. Direct immunofluorescence revealed IgM, IgA, C3, and fibrinogen deposition in 
the small vessels of the dermis.  
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In our opinion, there was strong evidence for drug-induced toxicity as the cause of the 
vasculitis, so chemotherapy with oxaliplatin was discontinued. The patient was treated with 
prednisolone at a decreasing dosage for the next 6 weeks. Under the steroid therapy, the 
vasculitis lesions disappeared rapidly. 
The  patient’s  general  practitioner  continuously  monitored  creatinine  clearance  and 
proteinuria.  After  2  weeks,  there  was  evidence  of  hematuria  (>20  erythrocytes)  and 
proteinuria (745 mg/l). The urine analysis showed an increase in renal parameters with 
creatinine 2.41mg/dl, urea 43 mg/dl, eGFR 26.3, a proteinuria of 1,800 mg/day in a 24-hour 
urine collection, and a creatinine clearance of 40.1 ml/min. The patient was admitted to the 
Department of Nephrology with the clinical diagnosis of acute renal failure, presumably as a 
consequence of acute glomerulonephritis. The percutaneous renal biopsy showed a focal 
segmental  extravascular  necrotizing  proliferating  glomerulonephritis.  Because  GBM-
antibodies (0.4 U/ml) or cryoglobulins (<0.2%) were not detectable, the most likely cause of 
renal failure was a renal manifestation of the leukocytoclastic vasculitis. Under high-dose 
steroid  therapy (prednisolone 250  mg for  3  days  followed  by  tapered  doses),  the  renal 
function improved slowly. 
Unfortunately, during further follow-up, the patient had developed tumor progression 
with  pulmonary  metastases  at  the  12-month  follow-up  visit.  Consequently,  a  palliative 
regimen  with  FOLFIRI  (5-FU,  leucovorin  and  irinotecan)  was  scheduled.  Under  this 
treatment, no side effects were apparent and the metastases remained stable for 8 months. 
Recent MRI and CT scans revealed a progressive disease with new metastasis-like lesions in 
the  thoracic  spine  and  suspect  lymph  nodes  in  the  retroperitoneal,  iliacal  and  inguinal 
region. 
Case 2 
We also treated a 71-year-old male patient with similar symptoms after chemotherapy 
with  FOLFOX-6  and  bevacizumab  for  colon  cancer  with  hepatic  metastases  [pT3,  pN0 
(0/33), pM1 (hepatic), G2, R0]. Initially, he had received surgical treatment with a right 
hemicolectomy and an atypical liver resection of some of the lesions. After the subsequent 
postoperative chemotherapy with FOLFOX-6 and bevacizumab for 4 cycles, restaging was 
performed.  Due  to  the  remaining  hepatic  metastases,  a  right  hemihepatectomy  was 
performed. Postoperatively, the patient developed ubiquitous petechial hemorrhage. Except 
for  increased  S-ANA-IF  activity  (1:320),  the  rheumatoid  factors  were  negative.  A  punch 
biopsy from an active hemorrhagic lesion again confirmed the diagnosis of a leukocytoclastic 
vasculitis.  Shortly  after  diagnosis,  the  patient  showed  clinical  symptoms  of  acute  renal 
failure and his renal parameters increased to a serum creatinine of 2.5 mg/dl and an urea of 
69 mg/dl, necessitating forced diuresis in addition to systemic corticosteroids for the next 2 
months. The nephrotic syndrome with microhematuria persisted for 2 months of continued 
cortisone therapy.  
A renal biopsy was repeated 2 months later and showed an IgA nephritis with focal 
segmental and global glomerulosclerosis. As treatment for the chronic renal failure grade III, 
a continuous cortisone therapy was prescribed. Assuming that drug toxicity was the cause of 
the vasculitis, the supporting chemotherapy was prematurely terminated.  
Within the following 12 months, the patient regretfully developed new metastases in the 
right lung segment and also showed bifocal liver metastases in the remaining left liver lobe. 
Therefore, he was treated with a modified FOLFIRI 14. The dose reduction was 75% and he 
received  additional  fluids  for  renal  protection.  Under  this  treatment,  the  patient  again  
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suffered  from  acute  or  chronic  renal  failure,  which  made  hemodialysis  necessary.  The 
cortisone therapy was continued.  
Conclusions 
Oxaliplatin is a third-generation platinum alkylating agent currently used to treat a great 
number of malignancies, including both locally advanced and metastatic colorectal cancer. 
Unfortunately, the use of oxaliplatin is associated with a plethora of adverse effects. While 
some of these effects,  like nausea or thrombocytopenia,  are common reactions to many 
cytostatic drugs, oxaliplatin has been reported to induce some rather unique side effects. 
With the report of these 2 cases, we have documented a very rare oxaliplatin-induced side 
effect  with  a  potentially  dramatic  impact  on  the  affected  patients.  Physicians  should  be 
aware of this rare, yet potentially detrimental adverse effect of oxaliplatin when employing it 
as a standard chemotherapeutic substance or as a part of novel combination therapies. 
To our knowledge, there has been only 1 case report prior to our observations reporting 
leukocytoclastic vasculitis as an adverse effect of treatment with oxaliplatin [15]. 
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Fig.  1.  Macroscopic  lesions  in  leukocytoclastic  vasculitis.  Skin  lesions  of patient  2  after  exposure  to 
oxaliplatin in a FOLFOX regimen against metastatic colon cancer. 
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Fig. 2. Immunohistochemical staining for chloroacetate esterase, CD15 and direct immunfluorescence for 
C3 and IgA. Skin biopsy from an area with macroscopic lesions. Chloroacetate esterase staining (CAE; a) 
and immunohistochemical staining for CD15 (b) showed accumulations of granulocytes surrounding the 
small vessel walls. Direct immunofluorescence showed complement factor C3 (c) and IgA deposits (d) 
within the small vessels of the papillary dermis. 
 